Form 8-K - Current report:
SEC Accession No. 0001104659-25-056996
Filing Date
2025-06-06
Accepted
2025-06-06 06:03:07
Documents
12
Period of Report
2025-06-05
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517353d1_8k.htm   iXBRL 8-K 24541
  Complete submission text file 0001104659-25-056996.txt   189670

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20250605.xsd EX-101.SCH 3020
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20250605_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20250605_pre.xml EX-101.PRE 22362
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2517353d1_8k_htm.xml XML 3704
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 251028757
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)